Novavax, Inc. (NASDAQ:NVAX) is back in the spotlight as its stock skyrockets following a wave of positive news about its COVID-19 vaccine. The FDA has notified Novavax that it completed the filing ...

How the United States' potential fourth vaccine stacks up against existing ones. Maryland-based biotech company Novavax said Monday that its COVID-19 vaccine was shown to be highly effective in ...

Lots of people are hearing about Novavax, the fourth COVID vaccine option in the U.S., for the first time, but it’s been authorized for use as a primary vaccine series since early 2022. Previously, it ...

The US Food and Drug Administration has delayed granting full approval of Novavax’s Covid-19 vaccine despite it being on track to be cleared until Tuesday afternoon, a person familiar with the ...

The US Food and Drug Administration has discussed with vaccine-maker Novavax the need for an additional trial of its Covid-19 vaccine as a post-approval commitment, a source familiar with the matter ...

Novavax shares currently trade at an extremely modest price-to-sales ratio. The company has previously raised concerns about its ability to survive as a business. Demand for COVID shots has been low, ...

Novavax (NVAX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Over the ...

The consensus analyst price target for Novavax stock has edged up from $12.50 to $13.21, reflecting an evolving outlook as the company navigates a transition in its business strategy. This shift ...

Six months after announcing a first wave of cost cuts, Novavax is instituting another round, looking to shave off a further $300 million in spending with more layoffs on the way. The drug developer, ...

It’s fall, which means it’s time to get updated on the winter season shots. That includes vaccines for flu, RSV (for babies and the elderly) and, for anyone six months or older, COVID-19. While the ...